Medicine

Pulmonary fibrosis is diagnosed in about 50,000 new patients annually, and as many as 40,000 Americans die from it each year

The pandemic has spotlighted ways to make clinical trials easier on patients and better for science, a heart drug researcher says

Reactions reflect unique features of an individual’s immune system, not the strength of a response

Willingness is rising, even among skeptical groups, at a time when there are still not enough doses to go around

Uptake by patients and physicians has been low in the U.S. even though some therapies have been authorized for months

Trials of all three vaccines came up with different efficacy numbers, but all offer crucial protection in this health emergency

Trusted messengers and repeated reminders can overcome hesitancy, social science shows

Scientific American talked to scientists about everything from what efficacy means to protection against the new coronavirus variants

Vaccine makers are designing follow-up shots based on new mutations to keep the disease at bay

As more coronavirus vaccines are rolled out, researchers are learning about the extent and nature of side effects

Antibiotics abound, but virus-fighting drugs are harder to come by. Fortunately, scientists are getting better at making and finding them

Some evidence indicates that short waits are safe, but there is a chance that partial immunization could help risky new coronavirus variants to develop